Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC 2024-09-19 09:00
50% ORR: Impressive Clinical Trial Data for Irpagratinib Combined with Atezolizumab in Advanced Hepatocellular Carcinoma Stuns ESMO-GI Congress 2024-06-28 10:30
Abbisko Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib 2024-04-09 08:30
Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021） 2024-01-09 08:30
Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021) 2023-12-14 08:30
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck 2023-12-04 21:05
87.5% ORR | Abbisko presented two clinical updates of Pimicotinib at the 2023 CTOS Annual Meeting 2023-11-07 12:31
Abbisko will debut two blockbuster clinical research results at the 2023 European Society for Medical Oncology（ESMO） 2023-10-16 21:50
Abbisko presented two preclinical research results at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC-NCI-AACR) 2023-10-16 18:20
77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting 2023-05-28 21:00
Abbisko presents the research results of 5 programs at the 2023 AACR Annual Meeting 2023-04-17 08:30
The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial 2023-03-16 10:00
Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376 2023-03-02 19:15
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021） 2023-01-30 11:00
Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021） in cGVHD 2023-01-18 07:00
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061 2022-07-04 13:34
Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules 2022-01-18 10:41
Qiming's Portfolio Company Abbisko Lists on Main Board of HKEx 2021-10-15 12:00
1